For research and educational purposes only. Not medical advice.
RAD-140 Reference
Educational, not medical advice reference for RAD-140: SARM, Recovery; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Phase 1 first-in-human oncology data in postmenopausal women with hormone-receptor-positive breast cancer exist; the trial excluded HER2-positive patients and did not advance to FDA approval. No body-composition human trials exist.
- Categories
- SARM, Recovery
- Aliases
- Testolone, Non-steroidal SARM
- Evidence posture
- human — FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 anabolic agents at all times, in and out of competition. No FDA-approved drug label and no human clinical efficacy program for body-composition use. Some US states have placed RAD-140 under Schedule III; possession without a prescription may be a state-level controlled-substance offense.
- Regulatory status
- No FDA-approved RAD-140 drug label. FDA has issued explicit consumer warnings against SARMs in bodybuilding products. WADA prohibits RAD-140 under category S1.2 anabolic agents at all times. Several US states have placed RAD-140 under state-level Schedule III provisions; federal scheduling status varies.
- Content review status
- research reference
Selected public sources
- FDA consumer update: SARMs are not FDA-approved and cannot be legally marketed as dietary supplements
- WADA prohibited list: SARMs are category S1.2 anabolic agents prohibited at all times
- ClinicalTrials.gov NCT03088527: first-in-human RAD140 study in hormone-receptor-positive breast cancer
- PubMed search: RAD-140 (Testolone) literature